Introduction
============

Laryngeal cancer is one of the most common Head and Neck cancers. For stage III-IV of this tumor, it can be treated by chemoradiation followed by salvage surgery or surgery and adjuvant radiotherapy (Lefebvre et al., 2010). Surgical treatment of this stage laryngeal cancer often need total removal of the larynx. As a result, patients underwent permanent tracheostomy and had speech and communication problems (Rizzo et al., 2008). These multimodalities are equivalent in terms of survival. However, patients who are treated with upfront chemoradiation can preserve their larynx which extremely affected their quality of life (Lefebvre et al., 2010; Kogashiwa et al., 2009). In 2003, there was a randomized control trial about concurrent chemoradiation for laryngeal preservation, which was updated at the 2006 American Society of Clinical Oncology annual meeting. The study showed that the 5-year laryngeal preservation rate was 83.6 % in concurrent chemoradiation group, 70.5 % in induction chemotherapy group and 65.7% in radiation alone. However, the overall survival rate and progression free survival rate were not different. Furthermore, the meta-analysis of chemotherapy in Head and Neck cancer demonstrated that concurrent chemoradiation had significant 5-year survival benefit (8%) compared with radiation alone. In contrast, adjuvant and induction chemotherapy did not improve survival outcome. Consequently, concurrent chemoradiation is likely to be the most appropriate treatment in stage III-IV laryngeal cancer to preserve the larynx (Rizzo et al., 2008). In spite of these benefits, concurrent chemoradiation had considerably acute and late complications, especially dysphagia and recurrent aspirated pneumonia. Therefore, the need to identify the patients who are suitable for upfront surgery or laryngeal preservation by concurrent chemoradiation is very important. Many recent studies revealed that factors related with treatment failure include stage, hemoglobin level, male gender, continued smoking and large tumor volume. Rodriguez et al., (2008) explored retrospectively about clinical predictors of successful laryngeal preservation. They found that increased age and continued smoking affected poorer overall survival outcomes. However, there is no study of clinical predictors related with laryngeal preservation rate treated with concurrent chemoradiation in Thailand.

Materials and Methods
=====================

This retrospective study was performed at Department of Radiation Oncology, Rajavithi Hospital, Thailand, From January 2010 to October 2014.The patients who were diagnosed with Laryngeal and hypopharyngeal cancer clinical stage III-IV and treated with organ preservation were assessed retrospectively. Enrollment in these studies was limited to patients with age of 20-70 years, pathological reports-proven squamous cell carcinoma and had medical history, treatment and follow-up records in Rajavithi Hospital. Exclusion criteria were patients who had prior laryngectomy, prior radiation at Head and Neck area, receiving radiation dose less than 45 Gray, had impaired renal function (GFR \<40), had poor liver function test, and poor performance status (ECOG \> 2), had evidence of distant metastasis, who were pregnant or lactating and who had two primary cancers. Neoadjuvant chemotherapy is allowed when followed by concurrent chemoradiation.

###### 

Baseline Characteristics

  -------------------------------------------------------------------------------------------
  Characteristics                                                             N = 69
  ------------------------------------- ------------------------------------- ---------------
  Age                                   Median (range)                        54 (24-76 )

  Gender                                Female\                               2 (2.9 %)\
                                        Male                                  67 (97.1%)

  Co-morbidity                          No\                                   52 (75.4 % )\
                                        Yes                                   17 (24.6 %)

  ECOG[a](#TFN1){ref-type="table-fn"}   0-1\                                  52 (75.4 %)\
                                        2                                     17 (24.6 % )

  Patho                                 SCC[b](#TFN2){ref-type="table-fn"}\   63 (91.3 % )\
                                        Non SCC                               6 (8.7% )

  Primary site                          Larynx                                

  Supraglottic\                         13 (18.9 % )\                         
  Glottic\                              14 (20.3 % )\                         
  Subglottic                            1 (1.5 %)                             

  Hypopharynx                                                                 

  Pyriform sinus\                       28 (40.6 % )\                         
  Post cricoid\                         8 (11.6 %)\                           
  Posterior pharyngeal wall             5 (7.1%)                              

  T stage                               T1\                                   7 (10.1 %)\
                                        T2\                                   14 (20.2% )\
                                        T3\                                   22 (31.9% )\
                                        T4                                    26 (37.8% )

  N stage                               N0\                                   22 (31.9 % )\
                                        N1\                                   18(26.1% )\
                                        N2\                                   18 (26.1% )\
                                        N3                                    11(15.9 % )

  Group stage                           III\                                  25 (36.2%)\
                                        IVa-b                                 44 (63.8%)

  Tumor grade                           Well differentiation\                 15 (21.7%)\
                                        Moderate differentiation\             32 (46.4%)\
                                        Poorly differentiation\               6 (8.7%)\
                                        unknown                               16 (23.2%)

  True vocal cord involvement           No\                                   41 (59.4 % )\
                                        Unilateral\                           20 (29.0 % )\
                                        Bilateral                             8 (11.6% )

  Cord fixation                         Absence\                              51 (73.9%)\
                                        Presence                              18 (26.1%)

  Upper airway obstruction              Absence\                              54 (78.3% )\
                                        Presence                              15 (21.7%)

  Dose                                  45-50 Gy\                             14 (20.3%)\
                                        51-60 Gy\                             2 (2.9 %)\
                                        61-70 Gy                              53 (76.8%)

  Treatment break                       None\                                 49 (71.0 %)\
                                        ≤ 1 wk\                               18 (26.1%)\
                                        \>1wk but \<2 wk                      2 (2.9%)

  Technique                             Two-dimensional\                      2 (2.9%)\
                                        Three- dimensional                    67 (97.1%)

  CMT[c](#TFN3){ref-type="table-fn"}    Cis/carboplatin weekly\               49 (71.0%)\
                                        Cis/carboplatin-5FU\                  7 (10.1%)\
                                        Other\                                1 (1.4%)\
                                        None                                  12 (17.5%)

  Hemoglobin level                      Mean +/- SD                           11.4 +/- 1.7

  Creatinine level                      Mean +/- SD                           0.8+/-0.1

  Smoking continuation                  No\                                   66 (95.6% )\
                                        Yes                                   3 (4.3%)

  Alcohol continuation                  No\                                   68 (98.5 %)\
                                        Yes                                   1 (1.5%)

  Salvage surgery                       No\                                   63 (91.3%)\
                                        Yes                                   6 (8.7%)
  -------------------------------------------------------------------------------------------

, Eastern Cooperative Oncology group(ECOG) performance status scale;

, Squamous cell carcinoma;

, chemotherapy.

###### 

Univariate Analysis of Possible Prognostic Factor

  --------------------------------------------------------------------------------------------------------------------------
  Variables                                                                          N     Median survival (mo.)   P-value
  -------------------------------------------- ------------------------------------- ----- ----------------------- ---------
  Age                                          \>60\                                 19\   23.3 (6.30,40.26)\      0.221
                                               \<60                                  50    10.2 (5.23,15.16)       

  Underlying\                                  No\                                   52\   9.9 (4.48,15.31)\       0.313
  disease                                      Yes                                   17    14.5 (9.66,19.34)       

  ECOG[a](#TFN4){ref-type="table-fn"}          0-1\                                  52\   14.7 (10.98,18.41)\     \<0.001
                                               2                                     17    7.2 (3.16, 11.23)       

  Primary\                                     Larynx\                               28\   14.5 (12.0-17.0)\       0.504
  Site                                         Hypopharynx                           41    8.5 (5.3,11.7)          

  Patho                                        SCC[b](#TFN5){ref-type="table-fn"}\   63\   12.2 (7.86,16.53)\      0.709
                                               Non SCC                               6     6.8 (0,45.49)           

  T stage                                      T1\                                   7\    Not reach\              0.133
                                               T2\                                   14\   12.8 (6.93,18.66)\      
                                               T3\                                   22\   7.8 (0,15.95)\          
                                               T4                                    26    7.2 (4.70,9.69)         

  N stage                                      N0\                                   22\   12.2 (4.59, 19.80)\     0.01
                                               N1\                                   18\   23.3 (11.45,35.15)\     
                                               N2\                                   18\   7.20 (5.67,8.72)\       
                                               N3                                    11    5.1 (0.50, 9.69)        

  Group stage                                  III\                                  25\   23.3 (11.25, 35.34)\    0.024
                                               IV                                    44    7.6 (4.89,10.30)        

  Volume                                       \<10ml\                               36\   16.6 (4.67,28.53)\      0.147
                                               \>=10ml\                              21\   8.2 (5.21,11.19)        
                                               unknown                               10                            

  Cord\                                        No\                                   41\   16.4 (10.17,22.63)\     0.042
  Involvement                                  Unilateral\                           26\   7.6 (4.60,10.60)\       
                                               Bilateral                             2     3.0                     

  Cord\                                        No\                                   51\   14.5 (10.13,18.87)\     0.245
  Fixation                                     Yes                                   18    7.2 (5.95,8.45)         

  UAO[c](#TFN6){ref-type="table-fn"}           No\                                   54\   14.7 (10.20,19.20)\     0.007
                                               Yes                                   15    7.20 (6.58, 7.82)       

  Dose                                         45-50 Gy\                             14\   7.2 (5.46,8.94)\        \<0.001
                                               51-60 Gy\                             2\    1.6\                    
                                               61-70 Gy                              53    15.4 (9.69,21.11)       

  Treatment\                                   None\                                 49\   35.6 (9.06,18.94)\      0.741
  Break                                        ≤ 1 wk\                               18\   8.2 (3.63,12.77)\       
                                               \>1-2 wk                              2     8.5                     

  Type of CMT[d](#TFN7){ref-type="table-fn"}   Cis/carbo weekly\                     49\   14.5 (10.93,18.07)\     0.086
                                               Cis/carbo+5FU\                        7\    7.6 (0,17.87)\          
                                               Other\                                1\    14.0                    
                                               None                                  12                            

  Smoking\                                     No\                                   66\   12.2 (7.82,16.51)\      0.461
  Continuation                                 Yes                                   3     7.2                     

  Alcohol\                                     No\                                   68\   11.1 (6.55,15.65)\      0.970
  continuation                                 Yes                                   1     16.4                    

  Salvage surgery                              No\                                   63\   9.9 (5.45,14.34)\       0.073
                                               Yes                                   6     42.0 (14.6,69.40)       

  Recurrence                                   No\                                   33\   14.0 (1.55,26.44)\      0.070
                                               Yes                                   36    10.2 (4.76,15.63)       

  Larynx\                                      No\                                   35\   11.1 (5.42,16.77)\      0.099
  preserve                                     Yes                                   34    12.8 (1.94,23.65)       

  Distant\                                     No\                                   62\   11.1 (6.27,15.92)\      0.579
  Metastases                                   Yes                                   7     12.8 (0,28.45)          
  --------------------------------------------------------------------------------------------------------------------------

, Eastern Cooperative Oncology group (ECOG) performance status scale;

, Squamous cell carcinoma;

, upper airway obstruction;

, chemotherapy.

###### 

Univariate Analysis of Factor that Affected Laryngeal Preservation

  ------------------------------------------------------------
  Variables                   Median survival mo.)   P-value
  ------------- ------------- ---------------------- ---------
  Group stage   III\          21.9 (0.35,43.44)\     0.046
                IV            5.4 (1.05,9.74)        

  Volume        \<10ml\       35.4 (5.14,65.65)\     0.005
                \>=10ml\      1.3 (0.35,2.25)        
                unknown                              

  Cord\         No\           15.5 (0.90,30.09)\     0.016
  Involvement   Unilateral\   11.7 (6.60,16.79)\     
                Bilateral     0.5                    

  N stage       N0\           12.3 (6.50,18.09)\     0.008
                N1\           16.9 (0-36.25)\        
                N2\           Not reach\             
                N3            1.3 (0.92,1.68)        

  Dose          45-50 Gy\     2.3 (0.34,4.26)\       \<0.001
                51-60 Gy\     0.5\                   
                61-70 Gy      19.2 (7.63,30.77)      

  Treatment\    None\         12.3 (2.71,21.88)\     0.017
  Break         ≤ 1 wk\       11 (0,23.16)\          
                \>1-2 wk      1.1                    
  ------------------------------------------------------------

###### 

Multivariate Analysis of Prognostic Factor for 69 Patients who were Treated with Organ Preservation

                                                                      Hazard ratio (95%CI)   P-value
  ------------------------------------------------------------------- ---------------------- ---------
  ECOG[a](#TFN8){ref-type="table-fn"} 2 vs 0-1 N stage                2.48 (1.19-5.17)       0.016
  N stage                                                                                    
  N0                                                                  Ref (1)                
  N1                                                                  0.70 (0.22-2.19)       0.545
  N2                                                                  0.49 (0.15-1.61)       0.240
  N3                                                                  0.98 (0.35-2.71)       0.961
  Group stage 4 VS 3 Vocal cord inv.[b](#TFN9){ref-type="table-fn"}   1.33 (0.64-2.77)       0.442
  Vocal cord inv.[b](#TFN9){ref-type="table-fn"}                                             
  None                                                                Ref (1)                
  Unilateral                                                          0.13 (0.02-0.70)       0.017
  Bilateral                                                           0.19 (0.03-0.94)       0.042
  UAO[c](#TFN10){ref-type="table-fn"} vs none                         1.03 (0.44-2.38)       0.936
  Dose                                                                                       
  61-70 Gy                                                            Ref (1)                
  45-50 Gy                                                            1.40 (0.52-3.73)       0.496
  51-60 Gy                                                            1.53 (0.18-12.50)      0.690

, Eastern Cooperative Oncology group (ECOG) performance status scale;

, vocal cord involvement;

, upper airway obstruction

###### 

Multivariate Analysis of Factor that Affected Laryngeal Preservation for 69 Patients who were Treated with Organ Preservation

                                                    Hazard ratio (95%CI)   P-value
  ------------------------------------------------- ---------------------- ---------
  N stage                                                                  
  N0                                                Ref (1)                
  N1                                                0.22 (0.04-1.27)       0.092
  N2                                                0.39 (0.07-2.01)       0.261
  N3                                                0.19 (0.04-0.77)       0.020
  Group stage 4 VS 3                                0.90 (0.28-2.81)       0.857
  Volume ≥10 ml VS less                             2.67 (1.02-7.01)       0.046
  Vocal cord inv.[a](#TFN11){ref-type="table-fn"}                          
  None                                              Ref (1)                
  Unilateral                                        0.80 (0.04-14.59)      0.881
  Bilateral                                         2.20 (0.13-35.86)      0.577
  UAO[b](#TFN12){ref-type="table-fn"} vs none       1.03 (0.44-2.38)       0.936
  Dose                                                                     
  61-70 Gy                                          Ref (1)                
  45-50 Gy                                          4.21(0.71-24.85)       0.122
  51-60 Gy                                          \<0.001                0.985
  Treatment break                                                          
  None                                              Ref (1)                
  ≤ 1 wk                                            0.07 (0.01-0.56)       0.013
  \>1-2 wk                                          0.05 (0.01-0.40)       0.004

, vocal cord involvement;

, upper airway obstruction
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All patients had a complete blood count, biochemical profile, chest X-ray and Head-and-neck CT scan before treatment. The patients were treated with conventional radiotherapy and standard fractionation, 2 Gray per day, 5 fractions per week. Dose range was 45-70 Gray. They were immobilized in a thermoplastic mask and treated on 6 MV linear accelerator. Dosimetry and treatment planning was performed with Xio version 4.8 with multileaf collimator 1 cm for two dimensional radiation and three dimensional radiation. The initial treatment volume including primary tumor, involved nodes and potential-microscopic spreading area were treated with 45-50 Gray at least. Dose for gross diseases were escalated to 66-70 Gray. Weekly or triweekly chemotherapy can be adding during radiation. Most patients (71%) received weekly platinum-based regimen and seven patients had cisplatin or carboplatin-5 FU given continuous infusion Day 1-4 and Day 21-24. Of the 69 patients who were enrolled in the study, only one underwent induction chemotherapy before radiation ([Table 1](#T1){ref-type="table"}).

Patients were evaluated at monthly intervals as a first follow up, after that every 3-4 months for the first two years and then every4-6 months for the next three years. Chest X-rays were annually examined. Residual disease defined as tumor still seen in originated tumor site within 6 months after completing the treatment. Recurrent tumor defined as presence of tumor more than 6 months after completing the treatment with tumor disappearance before. Suspected obtained sites of residual tumor or locoregional recurrence were evaluated with routine ENT examination and scope, CT scan and confirmed by histopathology. Disease suspected distant metastasis was examined by CT scan, Chest X-rays and bone scan, but was not routinely confirmed by biopsy. Salvage surgery or re-irradiation were considered in a patient with clinical or radiographic evidence of residual disease or locoregional recurrence. Chemotherapy was given in patient who accepted the treatment in case of distant metastasis or locoregional recurrence who cannot be treated with surgery or re-irradiation. In case of poor performance status or refusal of treatment, we treated the patients with best supportive care.

The statistical analysis was performed by SPSS version 17.0. A p-value of less than 0.05 were considered statistically significant. Overall survival, disease free survival and laryngeal preservation survival rate were calculated using the Kaplan-Meier method. Univariate correlation between these factors and patient age, stage, tumor grade, primary site were analyzed by log rank test and multivariate correlation were examined by Cox proportional hazards analysis.

Results
=======

Of 218 patients, 149 were excluded from the analysis for following reasons: prior glottis surgery (87 patients), withdrawal (7 patients), impaired renal function (7patients), impaired liver function (6 patients, developed metastasis (2 patients), developed two primary cancers (3 patients), loss of follow up (15 patients) and not fulfill radiation records (22 patients). Of the remaining 69 eligible patients, 25 and 44 were stage III and IV respectively. All the distribution of the primary site was 28 larynx and 41 hypopharynx. Of 69 patients, 67 were male and 2 were female, with a median age of 54 years (range 24-76). Patient characteristics are demonstrated in [Table 1](#T1){ref-type="table"}. Median follow up time was 6 months (range 0-46.3).

The mean Hemoglobin level was 11.4 +/- 1.7gm/dL. Most patients (46.4 %) had moderately differentiation pathology. Cord fixation and true vocal cord involvement was seen in 18 and 28 patients respectively. Only 15 patients complained of upper airway obstruction before or during radiation. None of the 69 patients had more than two weeks interruption during radiation. The treatment of 49 patients was not interrupted at all. During radiation, three of 69 patients continued smoking.

Two dimensional radiation was the treatment for 2 patients (2.9%), 67 patients (97.1 %) were treated with three dimensional radiation and none of patients was treated with Intensity Modulated Radiotherapy. Only one patient underwent induction chemotherapy before radiation. For laryngeal cancers, there were 21 patients received weekly regimens, 3 patients received triweekly regimen and 1 patients received other regimen (cetuximab). For hypopharyngeal cancer there were 28 patients received weekly regimens and 4 patients received triweekly regimen. With median follow-up time of 6 months (range 0-46.3), organ preservation controlled the disease with complete response in 14/28 (50%) evaluable glottis primaries and 19/41 (46.3%) evaluable hypopharynx primaries. Of 36 patients with residual disease or recurrent tumor, six were treated with salvage surgery, two were treated with tracheostomy, two were re-irradiated and four were given chemotherapy. In addition 22 patients were treated with best supportive care. In total, 53 of 69 patients received radiation dose of 61-70 Gray. After completing radiation, we found that 44 patients have no residual tumor within 6 months and 33 patients can preserve their functional larynx later with complete response (median follow up time 6 mo, range 0-46.3 mo). Of these 69, 36 has residual tumor or developed local relapse and seven were found to have metastasis. Median survival time was 12.2 months. The Kaplan-Meier 1-year, 2-year and 3-year overall survival was 50%, 33% and 25% respectively ([Figure 1](#F1){ref-type="fig"}). The 1-year, 2-year and 3-year locoregional free survival was 48 %, 36%and 31% respectively. The 1-year, 2-year and 3-year disease free survival was 42 %, 30 %and 22 % respectively. The 1-year, 2- year and 3-year laryngeal preservation rate was 49 %, 36 % and 32% respectively. Among the 36 patients with residual disease or local failure, there were 14 larynx primaries and 22 hypopharynx primaries. Local failure developed in 11 patients (31 %) with stage III disease and 25 patients (69%) with stage IV disease. Permanent tracheostomy was performed in patients or feeding tube dependence was detected in six patients. ECOG performance status 2, higher nodal stage, stage IV, presence of true vocal cord involvement, upper airway obstruction before/during radiation and radiation dose below 61-70 Gray had an effect on worse overall survival when evaluated with univariate analysis statistically significant ([Table 2](#T2){ref-type="table"}). Whereas there was no statistical significance between age, comorbidity, primary site, T stage, treatment break, type of chemotherapy, smoking history and overall survival rate. We also found that the patients with lower nodal stage (p = 0.008), stage III disease (p = 0.046), tumor volume \<10 ml (p = 0.005), no true vocal cord involvement (p = 0.016), dose 61-70 Gray (p \< 0.001) and no interruption of treatment (p = 0.017) have better laryngeal preservation survival rates on univariate analysis ([Table 3](#T3){ref-type="table"}). When a multivariate analysis was evaluated ECOG performance status 2 and presence of true vocal cord involvement factor was significantly associated with worse overall survival rate ([Table 4](#T4){ref-type="table"}). On multivariate analysis, we also demonstrated that tumor volume more than or equal 10 ml and treatment break more than one week was associated with inferior laryngeal preservation rate statistically significant ([Table 5](#T5){ref-type="table"}).

Discussion
==========

The study showed that 1-year, 2- year and 3-year laryngeal preservation rate was 49 %, 36 % and 32% respectively. According to our results, laryngeal cancer has no significant difference in overall survival rate when compared with hypopharyngeal cancer ([Figure 1](#F1){ref-type="fig"}).

Kogashiwa et al., (2009) examined laryngeal preservation strategies with induction chemotherapy followed by concurrent chemoradiation in locally advanced laryngeal and hypopharyngeal cancer. They found that laryngeal preservation rate is 93.8 % initially and 3 year rate is 57.8 %, which is higher than our study. Also, their findings have better 3 year overall survival rate (67%) since their protocol is more intensive than our study (all patients were treated with induction cisplatin and 5FU for two cycles before radiation and followed by concurrent chemoradiation with nedaplatin or docetaxel). Furthermore, their patients had better performance status (ECOG \<1).

Forastiere et al., (2006) investigated about the contribution of adding chemotherapy to radiation in laryngeal preservation strategies. They compared the results of induction cisplatin and 5FU followed by radiation, concurrent chemoradiation with cisplatin and radiation alone. The study showed that 5 year laryngectomy free survival rate is 45 % for sequential chemoradiation, 47% for concurrent chemoradiation and 34 % for radiation alone (p=0.011). As well as the study of Posner et al., (2009), the 3-year actuarial larynx preservation rate were 70 % with adding of docetaxel to induction chemotherapy regimen and 58 % with PF induction chemotherapy regimen (p=0.03). Whereas, the 3 year laryngeal preservation rate in our study was lower (32 %). As there was 17 % of patients who treated with radiation alone in our study. And, all patients was treated with the radiation dose 70 Gray in study of Forastiere et al., (2006) and chemotherapy regimen is triweekly or doublet chemotherapy regimen in the both studies, which is more intensive than ours.

In case of patient who unfit for received chemotherapy during radiation, Cetuximab plus radiation is an alternative choice for organ preservation modalities. Bonner et al., (2005) investigated about laryngeal preservation in locally advanced laryngeal cancer and hypopharyngeal cancer treated with radiation alone compared with Cetuximab plus radiation. They found that the rate of laryngeal preservation was higher when treated with Cetuximab plus radiation. In our study, there are only one patient received Cetuximab during radiation. The other 12 patients who unfit for chemotherapy cannot afford Cetuximab. So the laryngeal preservation rate was lower in our study.

For factors that affected laryngeal preservation in our study were nodal stage, group stage, tumor volume, true vocal cord involvement, radiation dose and treatment break time more than one week with statistical significance. When compared with other studies, the factor that affected on laryngeal preservation rate is also N-stage. Similarly, the study of Ramroth et al., (2011) found that patients with N1-N3 lymph node status was very strong factor on increase in mortality risk. The results showed that N1-N3 status had 3.5 fold increased mortality risk on overall survival. In addition, stage T3 to T4 have more than twice the mortality rate as much as stage T1 to T2 . Hence , T staging is also the prognostic factor that affected survival outcomes. In the same way, Rodrigez et al., (2008) found that patients with early T-stage have better survival outcomes and are treated with salvage surgery less than advanced T-stage with statistical significance. When we calculated the additional factor that impacted on survival outcomes in our study, we also found that patients with T1-T2 stage tended to have more median survival times (23.3 months) than patients with T3-T4 stage (7.8 months), p = 0.052.

Furthermore, there are 115 patients with stage II to IV laryngeal and hypopharyngeal cancer in study of Rodrigez et al., (2008). They were treated with conventional fractionated radiation 59 % and hyperfractionated radiation 41 %. The total dose was 68-72 Gray and concurrent with cisplatin and 5 FU for two cycles. Hence the treatment is more intensive than our study. They also found that continuation of smoking is one factor that affected laryngeal preservation.

Another factor that affected on laryngeal preservation rate is tumor volume. Strongin et al., (2012) analyzed the relationship between the primary tumor volume and cancer control in squamous cell cancer of the hypopharynx, oropharynx and larynx who treated with definitive chemoradiotherapy. The study demonstrated that tumor volume \< 35 cm^3^ had a better prognosis in terms of progression free survival (61% VS 33%, p =0.004) and overall survival (84 % VS 41 %, p \<0.001). Likewise our study, tumor volume (less than 10 ml) had better laryngeal preservation rate. However, T stage and N stage were not significant factor on recurrence or survival outcomes in the study of Strongin et al., (2012), contrast to our study. The possible reason that make this point different when compared to our study is most patients of their study were oropharyngeal cancer (65 %).

The recent study of Grover et al., (2015) investigated the pattern of care and survival outcomes in stage T4a laryngeal cancer treated with total laryngectomy, to compare with laryngeal preservation. The study showed that patients with laryngeal preservation has lower survival rate. On the contrary, the former studies demonstrated that there is no difference in survival aspect between total laryngectomy and laryngeal preservation in locally advanced laryngeal cancer, which may not be applied with stage T4a . Therefore, we implied that stage T4a may affect survival outcomes in laryngeal preservation.

Performance status is mentioned in the study of Grover et al., (2015) at one of the potentially important confounding factors. However, this wasn't recorded in the national cancer database, so the relationship between survival outcomes and performance status was not analyzed.

Moreover, other studies didn't demonstrate the relationship of the radiation dose and survival outcomes because it would increase the confounding effect.

The limitation of our study is the belated follow up of some patients, due to distance from the hospital to their accommodations. Although we plan to have a standard follow up and treatment, some recurrent patients cannot visit as soon as we expected. Their treatment was delayed, so their survival times were less than some patients in other studies.
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